Overview
The
Integrated Drug Resistance Action Framework for HIV, Hepatitis B and C,
and Sexually Transmitted Infections (2026–2030) outlines a unified
global approach to address drug resistance, a growing threat that risks
undermining decades of progress toward ending AIDS and the epidemics of
hepatitis B, hepatitis C, and sexually transmitted infections. Developed
through broad and inclusive consultation, and aligned with the WHO
Global Health Sector Strategies and the Sustainable Development Goals,
the framework promotes a people-centred approach and antimicrobial
stewardship across 5 key domains: prevention and response,
surveillance, research and innovation, laboratory capacity, and
governance.
Grounded
in equity and in a public health approach, the framework emphasises
country ownership and sustainability and encourages innovation while
strengthening strategic coordination and partnerships among governments,
communities, researchers, and global stakeholders. By integrating
disease-specific and cross-cutting actions, it aims to reinforce health
systems, expand access to high-quality and stigma-free services, and
preserve the effectiveness of lifesaving medicines.
Its goal is clear:
to prevent the emergence and spread of drug resistance so that efforts
to end AIDS and the epidemics of hepatitis B, hepatitis C, and sexually
transmitted infections as public health threats remain achievable by
2030.
Related
Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections